Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000438 · ClinicalTrials.gov registry record · Phase 4
Naltrexone Treatment for Alcoholism
A Phase 4 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 192
- Enrollment target
NCT00000438: Completed Phase 4 study, sponsored by Johns Hopkins University.
NCT00000438 is a Phase 4 study that has completed, run by Johns Hopkins University. The registered enrollment target is 192 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000438, a Phase 4 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 192 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness of the medication naltrexone (Revia) for treating alcoholism. Individuals will be inpatients for a 2 week period and provide assessments of their alcohol withdrawal symptoms, craving, and mood. Following hospital discharge, individuals will be assigned randomly to receive naltrexone daily, naltrexone twice a day or a placebo. This part of the study will last 12 weeks, with regular measurements of drinking level, craving and mood. Assessments will be conducted 6 and 12 months after the beginning of the study.
Interventions
- DRUG naltrexone (Revia)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Est. Completion | 2003-03 |
| Phase | Phase 4 |
What the finished NCT00000438 record still lists
NCT00000438 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 1 intervention - of which naltrexone (Revia) is the first listed.
NCT00000438 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000438 about?
NCT00000438 is a clinical study titled "Naltrexone Treatment for Alcoholism". This study will evaluate the effectiveness of the medication naltrexone (Revia) for treating alcoholism. Individuals will be inpatients for a 2 week period and provide assessments of their alcohol withdrawal symptoms, craving, and mood. Following hospital discharge, individuals will be assigned rand...
What is the current status of trial NCT00000438?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 192 participants. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00000438?
The interventions under investigation include: naltrexone (Revia) (DRUG).
Who is sponsoring clinical trial NCT00000438?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00000438's enrollment target sits among peer trials
192 451st of 2000 higher than 1,548 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease